

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 020759/020760

ADMINISTRATIVE DOCUMENTS/CORRESPONDENCE

ORIGINAL



APPEARS THIS WAY ON ORIGINAL

Central Research

BM

ORIG

December 11, 1997

Department of Clinical Research

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857



CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovafoxacin Mesylate)

Serial No. 079

NDA-20-760 - TROVAN® I.V. (Alatrofoxacin Mesylate Injection)

Serial No. 076 *(Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to the following teleconferences: an October 8, 1997 teleconference with Drs. Dan Davis and Regina Alivisatos, Medical Reviewers; an October 30, 1997 teleconference with Dr. Alivisatos and Dr. Brad Leissa, Medical Team Leader; and a November 11, 1997 teleconference with Dr. Leissa.

On October 8, 1997, Dr. Alivisatos asked if patients in study #154-144* of a lower socioeconomic status were harder to treat (Query #331). In response to this request Dr. Luke informed Dr. Alivisatos that patients of a lower socioeconomic status typically delayed seeking medical attention, placing them at risk for infection. In support of this answer, an August 1994 New England Journal of Medicine article was sent by facsimile on October 20, 1997. It is now being formally submitted to complete our records (Enclosure #1).

In support of our Nosocomial Pneumonia indication, on October 30, 1997 Dr. Alivisatos requested additional information substantiating the lack of direct association between Apache scores and severity of Nosocomial pneumonia (Query #385A). A draft response to this request was provided by facsimile on November 7, 1997. It is now being formally submitted to complete our records (Enclosure #2).

On November 10, 1997, Dr. Leissa asked Pfizer to justify the claim of TROVAN being equivalent to Ciprofloxacin for Nosocomial Pneumonia in light of the current labeling (Query #396). Dr. Leissa also asked Pfizer to please explain the conclusion previously stated that TROVAN is superior to the comparator (Query #397). A draft response to these requests was provided by Email and facsimile on December 4, 1997. It too is now being formally submitted to complete our records (Enclosure #3).

A desk copy of this cover letter is being provided to Pauline Fogarty, Project Manager.

Handwritten notes: "New" and "12/15/97" with a signature.



Dr. Goldberger, Director
NDA-20-759
NDA-20-760

2

December 11, 1997

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

Sincerely yours,

Linda Bullock

Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

*154-144- entitled "A Randomized, Double-Blind, Multicenter Trial Assessing the Safety and Efficacy of Intravenous Alatrofloxacin (CP-116,517) Followed by Oral Trovafloxacin (CP-99,219) Compared with Intravenous Cefoxitin Followed by Oral Amoxicillin/Clavulanic Acid for the Treatment of Acute PeM_c Infections."

lab
Enclosures
Desk Copy: Ms. P. Fogarty (cover letter)

APPEARS THIS WAY ON ORIGINAL

APPEARS THIS WAY ON ORIGINAL

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 411 4100

ORIGINAL



Central Research

BM
01/12/97

December 11, 1997



Department of Clinical Research

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunology
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

12/15/97

Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN[®] Tablets (Trovafloracin Mesylate)
Serial No. 78

NDA-20-760³ TROVAN[®] I.V. (Alatrofloracin Mesylate Injection)
Serial No. 75 *(Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION



Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to a November 26, 1997 facsimile from Dr. Philip Coyne, Medical Reviewer.

On November 26, 1997, Dr. Coyne requested a table of subjects that contained combinations of dizziness, nausea, or headache by treatment relatedness for each oral dose level, all multi-dose oral and IV-to-Oral regimens for the comparative Phase 2/3 trials (Query #418). A draft response to this request was provided by facsimile on December 2, 1997. It is now being formally submitted to complete our records.

A desk copy of this cover letter is being provided to Ms. Pauline Fogarty, Project Manager.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

Sincerely yours,

Linda Bulkinitch for:

Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

lab
Enclosure
Desk Copy: Ms. P. Fogarty (cover letter)

APPEARS THIS WAY ON ORIG

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100




BM
ORIG AMENDMENT

Central Research

December 9, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857



Department of Clinical Research

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN[®] Tablets (Trovafloracin Mesylate)
Serial No. 074

NDA-20-760 TROVAN[®] I.V. (Alatrofloracin Mesylate Injection)
Serial No. 071 (*Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION

Naci 12/15/97
[Redacted]

Reference is made to our pending New Drug Applications, submitted December 30, 1996.
Reference is also made to an October 10, 1997 teleconference with Dr. Regina Alivisatos,
Medical Reviewer.

On October 10 Dr. Alivisatos requested hard copies of radiology reports for certain patients in
study #154-113* (Query #325). On October 17 radiology reports were forwarded to Dr.
Alivisatos' attention via Federal Express for the following patients:

- | | |
|----------|----------|
| 51110083 | 65430540 |
| 51110108 | 65430809 |
| 51120277 | 51110106 |
| 51210230 | 51150122 |
| 51880004 | 51180069 |
| 54090358 | 52110782 |
| 54100363 | 53860247 |
| 54830113 | 54830116 |
| 54830115 | 54830254 |
| 55080613 | 55100609 |
| 55460090 | 55110619 |
| 55460091 | 55130622 |
| 65430538 | 56280117 |

APPEARS THIS WAY ON ORIGINAL

APPEARS THIS WAY ON ORIGINAL

These radiology reports are now being formally submitted to complete our records (Enclosure #1).

The last radiology report for patient 54090345 was provided by facsimile on December 5, 1997. It too is now being formally submitted to complete our records (Enclosure #2).

A desk copy of this cover letter is being provided to Ms. Pauline Fogarty, Project Manager.

December 9, 1997

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

APPEARS THIS WAY ON ORIGINAL

Sincerely yours,

Linda Bullonitch for:
Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

lab

Enclosures

Desk Copy: Ms. P. Fogarty (cover letter)

*154-113: entitled "A Randomized, Multicenter, Double-Blind, Double-Dummy Trial Comparing Intravenous Alatrofloxacin (CP-116,517) Followed by Oral Trovafloxacin (CP-99,219) with Intravenous Ciprofloxacin Followed by Oral Ciprofloxacin for the Treatment of Nosocomial Pneumonia."

APPEARS THIS WAY ON ORIGINAL

/s/

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100



014
ORIG AMENDMENT
ORIGINAL

Central Research


December 9, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

Department of Clinical Research

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER

Handwritten initials and date: *Na*, *12/15/97*



Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovafloracin Mesylate)

Serial No. 075

~~NDA-20-750~~ TROVAN® I.V. (Alatrofloracin Mesylate Injection)

Serial No. 072 (*Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION

Reference is made to our pending New Drug Applications, submitted December 30, 1996, and our submission of our draft package insert. Reference is also made to our teleconference of November 6, 1997 and an Email message on that same day from Dr. Brad Leissa, Medical Team Leader.

Dr. Leissa had requested a reanalysis of results from our complicated UTI program, including only those non-pyelonephritis patients infected with either *E. coli* or *K. pneumoniae* (Query #388) and to provide a revised labeling statement that highlights the efficacy in patients infected with these two organisms and restricting use to patients in whom the infecting organism is known prior to initiating treatment (Query #389).

Responses to Queries #388 and #389 are enclosed (**Enclosures #1 and #2**, respectively). The questions are bolded, followed by the replies in italics, or in the case of tables, in normal type.

Six desk copies of this submission are being provided to Ms. Fogarty for distribution to Medical Reviewers, Drs. Alivisatos and Leissa, Statistical Reviewers, Dr. Silliman and Jiang, and Dr. Goldberger.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

Sincerely yours,

Ronald I. Trust
Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

APPEARS THIS WAY ON ORIGINAL

rit
Enclosures
Desk Copies (6): Ms. P. Fogarty

APPEARS THIS WAY ON ORIGINAL

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100

BM

DRUG AMENDMENT

ORIGINAL



Central Research


December 9, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

Department of Clinical Research

Handwritten: 12/15/97
Handwritten: [Signature]

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.




Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovafoxacin Mesylate)
Serial No. 077

NDA-20-760* TROVAN® I.V. (Alatrofoxacin Mesylate Injection)
Serial No. 074 (*Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION



Reference is made to our pending New Drug Applications, submitted December 3, 1996. Reference is also made to an October 16, 1997 teleconference with Dr. Regina Alivisatos, Medical Director, Division of Special Pathogens and Immunologic Drug Products.

On October 16, 1997, Dr. Alivisatos requested any information available regarding the *in vitro* effects of trovafloxacin antagonism with aztreonam (Query #365). In response to this request, an abstract was forwarded to Dr. Alivisatos' attention by facsimile on October 21, 1997. It is now being formally submitted to our NDAs to complete our records.

A desk copy of this cover letter is being provided to Ms. Pauline Fogarty, Project Manager.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

Sincerely yours,

Handwritten signature: Ronald I. Trust
Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

lab
Enclosure
Desk Copy: Ms. P. Fogarty (Cover letter)

BB

ORIG AMENDMENT

ORIGINAL



Central Research


December 9, 1997

Department of Clinical Research

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

Nov 2/1997
[Redacted]

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.



Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovafoxacin Mesylate)
Serial No. 076

NDA-20-760 TROVAN® I.V. (Alatrofoxacin Mesylate Injection)
Serial No. 073 (*Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to November 24, and November 26, 1997 teleconferences with Dr. Philip Colangelo, Biopharmaceutics Reviewer.

On November 24, 1997, Dr. Colangelo requested literature references for PET study #154-024* (Query #414). These references were forwarded to his attention by facsimile on November 25 and 26, 1997. They are now being formally submitted to complete our records (Enclosure #1).

On November 26, 1997, Dr. Colangelo requested revised tissue levels from study #154-024 (Query #415) as well as dissolution data on the stability batches (Query #416). A table providing revised tissue levels from this study was forwarded to Dr. Colangelo's attention via facsimile on December 3, 1997. It is now being formally submitted to complete our records (Enclosure #2). Our response to the request for dissolution data on the stability batches was also provided by facsimile on December 3, 1997. It is also being formally submitted (Enclosure #3).

A desk copy of this submission is being provided to Dr. Colangelo. A desk copy of this cover letter is being provided to Ms. Pauline Fogarty, Project Manager.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

APPEARS THIS WAY ON ORIGINAL

Sincerely yours,

Ronald I. Trust
Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

APPEARS THIS WAY ON ORIGINAL

lab

Enclosures

Desk Copies:

Dr. P. Colangelo (Complete)
Ms. P. Fogarty (Cover letter)

*154-024- entitled "The Pharmacokinetics and Tissue Distribution Of [¹⁸F]-Trovafoxacin ([¹⁸F]-CP-99,219) in Man Utilizing Positron Emission Tomography (PET)."

CONFIDENTIAL

BW




ORIGINAL

Central Research

December 5, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunology
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857



Department of Clinical Research

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USC-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovafloracin Mesylate)
Serial No. 73
~~NDA-20-760~~ TROVAN® I.V. (Alatrofloracin Mesylate Injection)
Serial No. 70 (*Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION- COMMUNITY ACQUIRED PNEUMONIA

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to our November 14, 1997 telecon with the Division to discuss the Community Acquired Pneumonia (CAP) and Acute Exacerbation of Chronic Bronchitis (AECB) indications.

Prior to the meeting a table that combined organisms from all CAP studies to show Pfizer's total organism count for this indication was provided to Dr. Coyne by facsimile. This table is now being formally submitted to complete our records (Enclosure #1).

During this telecon Dr. Coyne requested new tables for subjects infected with either *C. pneumoniae*, *L. pneumophila*, or *S. aureus* that showed the incidence of these organisms when each was the sole pathogen or when they were co-pathogens. Dr. Coyne also requested the bacteriologic eradication rate for these pathogens as well as *M. catarrhalis* and *K. pneumoniae* (Query #400). A response to this request was provided by facsimile on November 17, 1997. It is now being formally submitted to our NDAs to complete our records (Enclosure #2).

A desk copy of this submission is being provided to Dr. Coyne. A desk copy of the cover letter is being provided to Ms. Pauline Fogarty, Project Manager.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

APPEARS THIS WAY ON ORIGINAL

Sincerely yours,
Dorinda Bullock for:
Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

lab
Enclosures
Desk Copies: Dr. P. Coyne (Complete)
Ms. P. Fogarty (Cover Letter)

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100



BM
ORIG AMENDMENT


Central Research

ORIGINAL

Department of Clinical Research

December 4, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857



APPE 12/4/97

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18- USC-1905
AND TO WHICH ALL CLAIMS OF
PRIVILEGE AND CONFIDENTIALITY ARE
ASSERTED IN BOTH STATUTORY AND
COMMON LAW. FURTHER
DISSEMINATION MAY ONLY BE MADE
WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovafloracin Mesylate)
Serial No. 072
NDA-20-760 - TROVAN® I.V. (Alatrofloracin Mesylate Injection)
Serial No. 069

RESPONSE TO FDA REQUEST FOR INFORMATION- ADVERSE REACTION OF DIZZINESS

Reference is made to our pending New Drug Applications, submitted December 30, 1996, and our submission of our draft package insert. Reference is also made to an Email message on October 24, 1997 from Dr. Brad Leissa, Medical Team Leader.

Dr. Leissa had requested a response to a series of ten questions addressing the adverse reaction of dizziness that has been associated with the use of Trovan (Query #369).

The enclosed response is provided in two parts. Part A (Enclosures 1 to 10) contains a direct response to each of the Division's questions. Each question is repeated in bold type, followed by Pfizer's response. For most of the questions, a table or figure was requested. The relevant tables or figures have been inserted following the brief comments for each question, if applicable. Part B (Enclosure #11) contains a discussion of our conclusions about dizziness associated with Trovan use, and draws from examination of our clinical data.

Draft copies of this submission was provided by facsimile on November 26, 1997 and by desk copies on December 2, 1997. This formal submission differs from the draft submission in the following ways: administrative edits were made to our response to Question #6; administrative edits were made to Enclosure #11, Part B, Section 2; administrative edits were made to Enclosure #11, Part B, Section 3.

Please note that Enclosure #11 contains data from study #154-046*. This study was not filed in our original NDAs. This information should be considered preliminary because analysis of this Phase I study is still in progress.

Desk copies of this submission are being provided to Ms. Fogarty for distribution to the Medical Reviewers, Statistical Reviewers and Dr. Goldberger.

Dr. Goldberger, Director
NDA-20-759
NDA-20-760

2

December 4, 1997

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

APPEARS THIS WAY ON ORIGINAL

Sincerely yours,

Linda Bulkowitch for:
Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

lab/rit
Enclosures
Desk Copies (12): Ms. P. Fogarty

154-046: Phase I, Double Blind, Parallel, Placebo Controlled Pilot Study to Assess the Safety, Toleration and Pharmacokinetics of Oral Trovafloxacin Administration as a Single Dose and in Divided Doses to Healthy Male Subjects.

APPEARS THIS WAY ON ORIGINAL

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100



BM
ORIG AMENDMENT
ORIGINAL

Central Research

December 3, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857



Department of Clinical Research
CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Nov 2/9/97
[Redacted]

Dear Doctor Goldberger:


RE: NDA-20-759 - TROVAN® Tablets (Trovafloracin Mesylate)
Serial No. 070

~~NDA-20-760~~ TROVAN® I.V. (Alatrofloracin Mesylate Injection)
Serial No. 068 (*Cover letter only)

CLINICAL INFORMATION AMENDMENT

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to our November 14, 1997 telecon with the Division to discuss the Community Acquired Pneumonia (CAP) and Acute Exacerbation of Chronic Bronchitis (AECB) indications.

(b)(4)



A desk copy of this cover letter is being provided to Ms. Pauline Fogarty, Project Manager and Dr. Coyne.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

APPEARS THIS WAY ON ORIGINAL



Sincerely yours,

Linda Bullock for:

Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

(b)(4)



lab


Enclosure
Desk Copies (cover letter): Ms. P. Fogarty and Dr. P. Coyne

BI

ORIG AMENDMENT



ORIGINAL



Central Research

December 2, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunology
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

Department of Clinical Research

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18- USC-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovafoxacin Mesylate)

Serial No. 67

NDA-20-760 TROVAN® I.V. (Alatrofoxacin Mesylate Injection)

Serial No. 66 *(Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION

Na
[Redacted] *12/9/97*

Reference is made to our pending New Drug Applications, submitted December 30, 1996.
Reference is also made to an October 24, 1997 telecon with Dr. Sousan Altaie, Microbiology
Reviewer.

Dr. Altaie had requested scattergrams on clinical microbiology data (Query #370). These
scattergrams were faxed to her attention on October 28, 1997. They are now being formally
submitted to complete our records.

A desk copy of this complete submission is being provided to Dr. Altaie. A desk copy of this
cover letter is being provided to Ms. Pauline Fogarty, Project Manager.

If you have any questions regarding this submission, please contact the undersigned at (860)
441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

Sincerely yours,

Linda Bulkowitch

Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

APPEARS THIS WAY ON ORIGINAL

lab
Enclosure
Desk Copy: Dr. S. Altaie (complete)
Ms. P. Fogarty (cover letter)




BM
ORIG AMENDMENT

ORIGINAL

Central Research

December 2, 1997

Mark Goldberger, M.D., Acting Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857



Department of Clinical Research

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Dear Doctor Goldberger:

RE: NDA-20-759- TROVAN® Tablets (Trovaflaxacin Mesylate)
Serial No. 068

~~NDA-20-760-~~ TROVAN® I.V. (Alatroflaxacin Mesylate Injection)
Serial No. 067 (*Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION- NON-GONOCOCCAL CERVICITIS
AND URETHRITIS

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to a May 13, May 19, May 21, May 22, June 4, and June 11, 1997 teleconferences with Dr. M. Makhene, Medical Reviewer.

On May 13, 1997, Dr. Makhene had requested assistance in preparing tables and listings to aid in her review of protocol #154-123*. Dr. Makhene requested the following (Query 146A):

- Preliminary listings of concomitant medication information to assist her in choosing drugs of interest to be included in subsequent patient listings. In response to this request, the tables were delivered on May 15, 1997:
 - ◆ "Indication" for Concomitant Antibiotics (Table NMED.1).
 - ◆ Reasons for concomitant antibiotics during study (Table NMED.2).
 - ◆ Con Meds by therapeutic class (Table NMED.3).
 - ◆ Con Meds by therapeutic class and prepared term (NMED.4).
- These tables are enclosed (Enclosure #1).
- Tables summarizing the number of patients randomized/treated/sponsor evaluable by center. In response to this request, Tables DM.1 and DM.2 were faxed to Dr. Makhene's attention on May 19, 1997. These tables are enclosed (Enclosure #2).
- Listing of reasons for non-evaluability. In response to this request, Dr. Makhene was referred to Table I of Appendix III of the study report.
- Listing of "relevant" concomitant medications for non-evaluable patients. This request was subsequent to Dr. Makhene's request for a preliminary listing of concomitant medication (Enclosure #1). In response to this request, Table DM.4 was provided by facsimile on May 22, 1997. This table is enclosed (Enclosure #3).
- Subject listing of day of assessment for first follow-up (EOT) with nominal window of day 8 to day 16. In response to this request, Tables DM.3.a and DM.3.b were faxed to Dr. Makhene's attention on May 19, 1997. These tables are enclosed (Enclosure #4).
- A listing of patients receiving ceftriaxone (as per protocol criteria) in order to allow assessment of "susceptibility pattern" and a listing of patients with unprotected sexual contact during study. In response to these request, Tables DM.5 and DM.6 were provided to Dr. Makhene by facsimile on May 22, 1997. These tables are enclosed (Enclosure #5).



ms B/9/97

December 2, 1997

- Summaries of patients with co-infections (i.e., chlamydia with GC) by site and gender along with outcomes for the sponsor's evaluable analysis. In response to this request, Dr. Makhene was referred to Tables 5.1.1 through 5.4.4 in the study report.

On June 4, 1997 and June 11, 1997 Dr. Makhene requested that the listing of patients with unprotected sexual contact (Table DM.6) be modified to display information only for bacteriologically evaluable patients and display the bacteriological response at the end of the study. In response to this request, Table DM.7 was faxed to Dr. Makhene's attention on June 4, 1997 (Enclosure #6, Query #146B and Query #192).

She also requested a listing of post baseline positive Chyamydia cultures. In response to these requests, Table DM.8 was forwarded to Dr. Makhene's attention on June 19, 1997. This table is enclosed (Enclosure #7, (Queries #170 and #191).

On June 11, 1997 Dr. Makhene requested that electronic files be provided for the following of the above mentioned tables (Query #171):

- Subject Counts by Center (Table DM.1)
- Subject Counts [Randomized vs. Sponsor Evaluable] by Center (Table DM.2)
- Listing of Patients with Unprotected Sexual Exposure (Table DM.6)

A "draft" diskette was forwarded to Dr. Makhene's attention on June 23, 1997. A QA'd diskette containing these files is currently being submitted to complete our records (Enclosure #8). This diskette has been scanned and is free of viruses.

A desk copy of this cover letter is being provided to Ms. Pauline Fogarty, Project Manager. If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991.

Please include this information in our files for NDA-20-759 and NDA-20-760.

Sincerely yours,

APPEARS THIS WAY ON ORIGINAL

Linda Bulkowitch for:
Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

*154-123- "A Randomized, Multicenter, Double-Blind, Double-Dummy Comparative Study of Trovafloxacin (CP-99,219) and Doxycycline for the Treatment of Uncomplicated Chlamydial Urethritis/Cervicitis" most recently amended on March 20, 1995 (b)(4)

lab

Enclosures

Desk Copy: Ms. P. Fogarty (Cover letter only)

NEW CORRESP

ORIGINAL

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100



Central Research


November 21, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

Department of Clinical Research

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USC-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION SHALL ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Handwritten: New 12/14/97
[Redacted]




Handwritten signature: [Signature]

Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovafloracin Mesylate)
Serial No. 64
NDA-20-760 - TROVAN® I.V. (Alatrofloracin Mesylate Injection)
Serial No. 63 (*Cover letter only)
RESPONSE TO FDA REQUEST FOR INFORMATION

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to a November 10, 1997 Email message and a November 11, 1997 telecon with Dr. Philip Coyne, Medical Officer.

(b)(4)



A desk copy of this submission is being provided to Dr. Coyne. A desk copy of the cover letter is being provided to Ms. Pauline Fogarty, Project Manager.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

Sincerely yours,

Handwritten signature: Ronald I. Trust

Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

APPEARS THIS WAY ON ORIGINAL

lab/rit

Enclosures

Desk Copies: Dr. P. Coyne (Complete)
Ms. P. Fogarty (Cover Letter)

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100



Central Research

October 29, 1997

BB
ORIG AMENDMENT

Department of Clinical Research

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

Handwritten signature/initials

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-115C-1005
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.



Dear Doctor Goldberger:

RE: NDA-20-759 - TROVAN® Tablets (Trovaflaxacin Mesylate)

Serial No. 059

~~NDA-20-760 - TROVAN® I.V. (Alatroflaxacin Mesylate Injection)~~

Serial No. 058 *(Cover letter only)

RESPONSE TO FDA REQUEST FOR INFORMATION

Reference is made to our pending New Drug Applications, submitted December 30, 1996.
Reference is also made to an October 7, 1997 telecon with Dr. Philip Colangelo,
Biopharmaceutics Reviewer.

Dr. Colangelo had requested dissolution data for the tablet ~~(b)(4)~~.
(b)(4) A response to this request was provided by facsimile on October 14, 1997. It is
now being formally submitted to complete our records.

A desk copy of this cover letter is being provided to Ms. Fogarty. A desk copy of this complete
submission is being provided to Dr. Colangelo.

If you have any questions regarding this submission, please contact the undersigned at (860)
441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.


APPEARS THIS WAY ON ORIGINAL

Sincerely yours,

Ronald I. Trust
Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

lab
Enclosures
Desk Copy: Ms. P. Fogarty (Cover letter only)
Dr. P. Colangelo (Complete)

Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100



Central Research

BM

October 23, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products HFD-590
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

Department of Clinical Research

msi 10/24/97

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Dear Doctor Goldberger:

RE: NDA-20-759- TROVAN[®] Tablets (Trovafloracin Mesylate)
Serial No. 58
NDA-20-760*- TROVAN[®] I.V. (Alatrofloracin Mesylate Injection)
Serial No. 57 *(Cover letter only)
RESPONSE TO FDA REQUEST FOR INFORMATION

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to a September 29, 1997 teleconference with Dr. Brad Leissa, Team Leader and his request that Pfizer reanalyze our efficacy results for TROVAN studies in which Dr. Fiddes participated (Query #308).

Dr. Fiddes participated in four TROVAN studies: studies #154-103**, #154-116[^], #154-109[^] and #154-114^o. Modified efficacy tables for these studies were forwarded by Federal Express to Ms. Fogarty's attention on October 13, 1997. Electronic copies of these tables were provided to Dr. Leissa on October 14, 1997 (Query #342).

A review of these tables suggests that removal of the efficacy results from Dr. Fiddes' center will not affect the overall conclusions from these studies.

A desk copy of this cover letter is being provided to Ms. Fogarty and Dr. Leissa.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

Sincerely yours,

Linda Bulkinitch for:

Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

APPEARS THIS WAY ON ORIGINAL

** study #154-103, entitled, "A Randomized, Double-Blind, Multicenter Trial Comparing 7 Days of Oral Therapy with Trovafloracin (CP-99,219) (100 mg or 200 mg Daily) or Ciprofloracin Hydrochloride (500 mg Daily) for the Treatment of Uncomplicated Urinary Tract Infections."

Mark Goldberger, Director
NDA-20-759
NDA-20-760

2

October 23, 1997

^study #154-116, entitled, "A Randomized, Double-Blind, Multicenter Trial Comparing 3 Days and 7 Days of Oral Therapy with Trovafloxacin (CP-99,219) (100 mg Daily) and 3 Days Therapy with Norfloxacin (400 mg BID) for the Treatment of Uncomplicated Acute Urinary Tract Infections."

^study #154-109, entitled, "A Randomized, Double-Blind, Multicenter Trial Comparing 7 Days of Oral Therapy with Trovafloxacin (CP-99,219) (100 mg Daily) and Clarithromycin (500 mg BID) for the Treatment of Acute Exacerbation of Chronic Bronchitis."


*study #154-114, entitled, "An Open, Noncomparative, Multi-Center Trial Designed to Assess the Efficacy and Safety of 10 Days Oral Therapy with Trovafloxacin (CP-99,219) (200 mg Once Daily) for the Treatment of Acute Sinusitis."

lab

Enclosures

Desk Copies: Ms. P. Fogarty (Cover letter only)
Dr. B. Leissa (Cover letter only)

APPEARS THIS WAY ON ORIGINAL



Central Research Division
Pfizer Inc
Eastern Point Road
Groton, CT 06340
Tel 860 441 4100

BB
~~NEW COURTESY~~
ORIG AMENDMENT



Central Research

Department of Clinical Research

October 21, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunology
Drug Products (HFD 590)
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

[Handwritten signature]
[Handwritten initials]

Dear Doctor Goldberger:

RE: NDA-20-759- TROVAN® Tablets (Trovafloracin Mesylate)
Serial No. 56
NDA-20-760*- TROVAN® I.V. (Alatrofloracin Mesylate Injection)
Serial No. 55 *(Cover letter only)
RESPONSE TO FDA REQUEST FOR INFORMATION

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to September 8 and 11, 1997 Email messages received from Dr. Philip Colangelo, Biopharmaceutics Reviewer. Reference is also made to a September 15, 1997 teleconference between Pfizer and Dr. Colangelo.

Dr. Colangelo had requested formulation details for the investigational formulations used in studies #154-028**, #154-042 (b)(4) A response to this request was provided by facsimile on October 3, 1997. It is now being formally submitted to complete our records (Enclosure #1).

(b)(4)

On September 4, 1997, Dr. B.V. Shetty, Chemistry Reviewer, asked for information on the alatrofloracin (TROVAN IV) formulation (Queries #273-280).

A response (normal type) to these questions (bold type) was provided by facsimile on October 3, 1997. It is now being formally submitted to complete our records (Enclosure #2).

A desk copy of this cover letter is being provided to Ms. Fogarty. Desk copies of this complete submission are being provided to Drs. Colangelo and Shetty.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

APPEARS THIS WAY ON ORIGINAL

Sincerely yours,

Linda Bultman

Ronald I. Trust, Ph.D., M.B.A.
Associate Director II

Dr. Goldberger, Director
NDA-20-759
NDA-20-760

2


October 21, 1997

Regulatory Affairs Department

** study #154-028, entitled, "An Open, 3-Period, 3-Treatment, Randomized Crossover Evaluation of the Bioavailability of Trovafloxacin (CP-99,219) Administered as an Oral Suspension (OS) in a Fasted and Fed State Relative to the Tablet Formulation in Healthy Subjects."

^study #154-042, entitled, "Phase I, Open-Labeled, Cross-Over, Bioequivalence Study of the Proposed Commercial Table of Trovafloxacin (CP-99,219) Relative to the Phase III Tablet in Healthy Subjects."

(b)(4)




lab

Enclosures

Desk Copy: Ms. P. Fogarty (Cover letter only)
Dr. P. Colangelo (Complete)
Dr. B.V. Shetty (Complete)

APPEARS THIS WAY ON ORIGINAL



NC
NEW CORRESP




Central Research

October 21, 1997

Department of Clinical Research

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products HFD-590
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #128-30
5600 Fishers Lane
Rockville, MD 20857



CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18- USC-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

[Handwritten signature]
[Redacted box]

Dear Doctor Goldberger:

RE: NDA-20-759- TROVAN® Tablets (Trovaflloxacin Mesylate)
Serial No. 057

NDA-20-760* TROVAN® I.V. (Alatroflloxacin Mesylate Injection)
Serial No. 056 *(Cover letter only)

GENERAL CORRESPONDENCE

Reference is made to our pending New Drug Applications, submitted December 30, 1996. Reference is also made to a September 26, 1997 teleconference with Dr. Regina Alivisatos, Medical Reviewer.

Dr. Alivisatos had requested a list of #154-113* investigator sites that had enrolled patients. A list was provided by Email on September 26, 1997 (Query #307). This list is now being formally submitted to our NDAs to complete our records (Enclosure #1).

Pfizer has taken the initiative to also provide a list of investigator sites that enrolled patients for study #154-137**. This list was provided to Dr. Alivisatos via Email on October 6, 1997. It is being formally submitted to our file to complete our records (Enclosure #2).

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991. Please include this information in our files for NDA-20-759 and NDA-20-760.

APPEARS THIS WAY ON ORIGINAL

Sincerely yours,

Linda Bulkowitch


Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

*154-113- entitled "A Randomized, Multicenter, Double-Blind, Double-Dummy Trial Comparing Intravenous Alatroflloxacin (CP-116,517) Followed by Oral Trovaflloxacin (CP-99,219) with Intravenous Ciproflloxacin Followed by Oral Ciproflloxacin for the Treatment of Nosocomial Pneumonia."

**154-137- entitled "A Randomized Multicenter Open Trial Comparing Intravenous Alatroflloxacin (CP-116,517) Followed by Oral Trovaflloxacin (CP-99,219) with Intravenous Ceftazidime Followed by Oral Ciproflloxacin with Optional Gentamycin and Vancomycin for the Treatment of Nosocomial Pneumonia."

lab
Enclosure

ORIGINAL



Central Research

Department of Clinical Research

October 9, 1997

Mark Goldberger, M.D., Director
Division of Special Pathogens and Immunologic
Drug Products HFD-590
Office of Drug Evaluation IV
ATT: DOCUMENT CONTROL ROOM #12B-30
5600 Fishers Lane
Rockville, MD 20857

CONFIDENTIAL/TRADE SECRET
INFORMATION SUBJECT TO 18-USE-1905
AND TO WHICH ALL CLAIMS OF PRIVILEGE
AND CONFIDENTIALITY ARE ASSERTED IN
BOTH STATUTORY AND COMMON LAW.
FURTHER DISSEMINATION MAY ONLY BE
MADE WITH THE EXPRESS WRITTEN
PERMISSION OF PFIZER INC.

Dear Doctor Goldberger:

RE: NDA-20-759- TROVAN® Tablets (Trovafloracin Mesylate)
Serial No. 52

RESPONSE TO FDA REQUEST FOR INFORMATION- CHEMISTRY, MANUFACTURING
& CONTROLS

Reference is made to our pending New Drug Application, NDA-20-759, submitted December 30, 1996.
Reference is also made to Trovan Tablet Chemistry, Manufacturing and Controls questions received
August 13, 1997 from Dr. B.V. Shetty, Chemistry Reviewer (Queries #258-264).

Enclosed are Pfizer's responses to these questions. Each question is repeated and followed by our
response.

A desk copy of this submission is being provided to Dr. Shetty. A desk copy of this cover letter is being
provided to Ms. Fogarty, Project Manager.

If you have any questions regarding this submission, please contact the undersigned at (860) 441-6991.
Please include this information in our files for NDA-20-759.

Sincerely yours,

Linda Bullonitch

Ronald I. Trust, Ph.D., M.B.A.
Associate Director II
Regulatory Affairs Department

APPEARS THIS WAY ON ORIGINAL

lab
Enclosure
Desk Copy: Ms. P. Fogarty (Cover letter only)
Dr. B. V. Shetty (Complete)